CAS: 15150-84-2; 3-Phenylpyridazine

该化合物是一种热循环芳香化合物,其特点是在三点方位用苯基组替代了一条环,这种结构具有独特的电子和消毒特性,使其成为制药和农用化学合成中有价值的中间体.其僵硬的芳香框架加强了分子相互作用的紧密联系,特别是在生物活性化合物的开发中.该复合物在普通有机溶剂中表现出良好的热稳定性和溶性,促进了其在各种化学转化中的使用.研究人员倾向于使用3-苯基丙胺,以利其多功能构建复杂的循环系统,在医药化学和材料科学应用中充当关键的手持手持者.

结构式图片

相似化合物

20375-65-9 58059-29-3 14966-91-7

欧盟法规

ECHA物质C&L通报

上下游产品

1,2-diazine phenyllithium 3-chloro-6-phenylpyradazine 6-phenyl-3(2H)-pyridazinethione 1-methyl-3-phenyl-pyridazinium; iodide 3-phenyl-hexahydro-pyridazine 3-amino-6-phenylpyridazine 4-amino-3-phenylpyridazine

合成工艺路线路线简述

    📜1-苯基-3-丁烯-1-醇置于jones Reagent,碘,二甲基亚砜,Sodium Hydroxide体系中,用 四氢呋喃,乙醚,乙醇 用作溶剂,化学反应 4.5H,反应生成3-苯基哒嗪
    参考文献:碘介导的二甲亚砜中 β,γ-不饱和腙的氧化环化:构建 1,6-二氢哒嗪和吡咯的策略
    标题:碘介导的二甲亚砜中 β,γ-不饱和腙的氧化环化:构建 1,6-二氢哒嗪和吡咯的策略
    摘要:简单的市售碘首次被成功地用作高效化学选择性催化剂,用于 β,γ-不饱和腙的氧化成环,从而在温和条件下生产 1,6-二氢哒嗪.有趣的是,当使用含有给电子基团(例如呋喃基,噻吩基和环烷基)的活性β,γ-不饱和腙化合物时,得到了吡咯.哒嗪的克级制备实验和进一步衍生化证明了我们的合成方法的潜在适用性.实验研究和密度泛函理论计算揭示了决定不同产物形成的化学选择性的起源.
    Doi:10.1021/acs.Joc.3C00669

    海关参考信息

    专利信息


    专利号:US-6225329-B1
    优先权日:1998-03-12
    标 题 :Modulators of protein tyrosine phosphatases (PTPases)
    发明人:RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOELLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
    权利人:NOVO NORDISK AS
    摘要:The present invention provides novel compounds of Formula 1, compositions containing these compounds, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like, n wherein A, R 1 , R 2 , R 3 , R 4 , R 16 and R 17 are as defined in the specification. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    专利号:US-2005119332-A1
    优先权日:1998-03-12
    标 题 :Substituted thiophene compounds as modulators of protein tyrosine phosphatases (PTPases)
    发明人:JEPPESEN LONE; ANDERSEN HENRIK S; OLSEN OLE H; JUDGE LUKE M; HOLSWORTH DANIEL D; BAKIR FARID; AXE FRANK U; GE YU
    摘要:The present invention provides novel compounds of formula 1a, n nnovel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    专利号:WO-9946244-A1
    优先权日:1998-03-12
    标题 :Modulators of protein tyrosine phosphatases (ptpases)
    发明人:JEPPESEN LONE; ANDERSEN HENRIK SUNE; OLSEN OLE HVILSTED; JUDGE LUKE MILBURN; HOLSWORTH DANIEL DALE; BAKIR FARID; AXE FRANK URBAN; GE YU
    权利人:NOVO NORDISK AS; ONTOGEN CORP
    摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    专利号:WO-9946267-A1
    优先权日:1998-03-12
    标题 :Modulators of protein tyrosine phosphatases (ptpases)
    发明人:MOELLER NIELS PETER HUNDAHL; ANDERSEN HENRIK SUNE; IVERSEN LARS FOGH; OLSEN OLE HVILSTED; BRANNER SVEN; HOLSWORTH DANIEL DALE; BAKIR FARID; JUDGE LUKE MILBURN; AXE FRANK URBAN; JONES TODD KEVIN; RIPKA WILIAM CHARLES; GE YU; UYEDA ROY TERUYUKI
    权利人:NOVO NORDISK AS; ONTOGEN CORP
    摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    专利号:US-6951878-B2
    优先权日:1998-03-12
    标 题:Benzo[b]thiophenyl or tetrahydro-benzo[b]thiophenyl modulators of protein tyrosine phosphatases (PTPases)
    发明人:MOELLER NIELS PETER HUNDAHL; ANDERSEN HENRIK SUNE; IVERSEN LARS FOGH; OLSEN OLE HVILSTED; BRANNER SVEN; HOLSWORTH DANIEL DALE; BAKIR FARID; JUDGE LUKE MILBURN; AXE FRANK URBAN; JONES TODD KEVIN; RIPKA WILLIAM CHARLES; GE YU; UYEDA ROY TERUYUKI
    权利人:NOVO NORDISK AS
    摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPase's) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. n The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    专利号:WO-9946236-A1
    优先权日:1998-03-12
    标题 :Modulators of protein tyrosine phosphatases (ptpases)
    发明人:RICHTER LUTZ STEFAN; ANDERSEN HENRIK SUNE; VAGNER JOSEF; JEPPESEN CLAUS BEKKER; MOELLER NIELS PETER HUNDAHL; BRANNER SVEN; SU JING; BAKIR FARID; JUDGE LUKE MILBURN
    权利人:NOVO NORDISK AS; ONTOGEN CORP
    摘要:The present invention provides novel compounds, novel compositions, methods of their use, and methods of their manufacture, where such compounds are pharmacologically useful inhibitors of Protein Tyrosine Phosphatases (PTPases) such as PTP1B, CD45, SHP-1, SHP-2, PTPα, LAR and HePTP or the like. The compounds are useful in the treatment of type I diabetes, type II diabetes, impaired glucose tolerance, insulin resistance, obesity, immune dysfunctions including autoimmunity diseases with dysfunctions of the coagulation system, allergic diseases including asthma, osteoporosis, proliferative disorders including cancer and psoriasis, diseases with decreased or increased synthesis or effects of growth hormone, diseases with decreased or increased synthesis of hormones or cytokines that regulate the release of/or response to growth hormone, diseases of the brain including Alzheimer's disease and schizophrenia, and infectious diseases.

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    摘要:Zhang, J., Science of Synthesis Knowledge Updates, (2010) 4, 268.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知